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Abstract— The synthesis of new potential adjuvant saponin aglycons was investigated by selective palladium mediated C-H
functionalisation of appropriately functionalized derivatives of lanosterol, cholesterol, and friedelin. The desired equatorial
aldehyde functionality was successfully introduced into the lanosterol skeleton as expected. Cyclopalladation of a cholesterol
derivative proceeded as expected, but during oxidation of the organopalladium intermediate, participation of the adjacent
alkene functionality led to stereoselective formation of a cyclopropane and introduction of an acetate group into the steroid
backbone at C-6. Further investigation of this unusual cyclopropane formation on a model decalin system confirmed the
result, but C-H activation on a related open chain system was prevented by complexation of the alkene functionality to the
palladium.
1. Introduction
The presence of an equatorial aldehyde substituent at the C-4 position of the triterpene unit seems essential to the
adjuvant activity shown by saponins1 such as QS21 which contain quillaic acid as the aglycon portion.2-5
We envisaged that the cyclopalladation reaction first reported by Shaw6 and subsequently studied by Baldwin7
and others8-10 would enable us to introduce the aldehyde functionality selectively into a range of rigid steroidal
and tritepenoid backbones, as it allows the activation of a C-H bond on an equatorial methyl group adjacent to an
oxime, via -organopalladium intermediates.
Figure 1
The cyclopalladation reaction takes place regioselectively and the stereochemistry of the complex formed
between the oxime function and the palladium was deduced by nOe studies by Baldwin et al.7 The exclusive
functionalization of the equatorial methyl group linked to the C-4 carbon is explained by the fact that the
cyclopalladation is facilitated by a coplanar arrangement of the oxime and the “target” methyl group.
* Corresponding author. Tel.: +44 20 7679 1503; fax: +44 20 7679 7524; e-mail: tom.sheppard@ucl.ac.uk.
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The cyclopalladation of appropriately functionalized derivatives of lanosterol (1), cholesterol (2), and friedelin
(3) (Figure 1) was therefore investigated with a view to exploring the potential of the Shaw reaction for
selectively introducing an equatorial aldehyde group and hence synthesising potential aglycons for new adjuvant
saponins.
2. Results and discussion
2.1. Preparation of Oximes
Lanosta-8,24-dien-3-one oxime (4),11 4,4-Dimethylcholest-5-en-3-one oxime (5)12-13 and friedelan-3-one oxime
(6) were prepared according to literature methods (Scheme 1).
Scheme 1 a. Jones’ reagent, acetone, 0 °C to rt. b. NH2OH.HCl, NaHCO3, EtOH, reflux. c. Br2, AcOH, NaOAc, Et2O, rt; Na2Cr2O7.2H2O,
AcOH, 90 °C then Zn, AcOH, pyridine, rt. d. K, tBuOH, MeI.
2.2. Cyclopalladation reactions
Dimeric organopalladium complex 7 was obtained as expected from the lanosterol derived oxime 4 by treatment
with Na2PdCl4 and NaOAc in AcOH (Scheme 2). The formation of the palladium dimer was evidenced by
disappearance of the NMR signal corresponding to the equatorial methyl group C-30, and the appearance of a
downfield resonance corresponding to the CH2Pd unit. The 13C resonance for C-30 could not be detected directly
but was observed in the 2D HMQC spectrum at approximately 42.5 ppm. The absence of this carbon signal from
the 13C spectrum is likely to be due to fluxional behaviour (vide infra). Acetylation of 7 with Ac2O in the
presence of Et3N and DMAP in CH2Cl2 gave an unstable acetate 8, which was immediately oxidized with
Pb(OAc)4 and pyridinium acetate in THF, followed by reductive workup with NaBH4 to afford the diacetate 9.
The selective introduction of the acetate at C-30 was confirmed by the presence of an AB methylene resonance
at 4.18 ppm. Deacetylation of 9 with Na2CO3 in MeOH gave the oxime 10, which was hydrolysed with TiCl3 in
aqueous THF to give the ketone 11. Transformation of 11 into the target aldehyde 12 was achieved in 52% yield
by oxidation with sulphur trioxide pyridine complex and DMSO in the presence of Et3N. This compares
favourably with the preparation of an ursolic acid derivative by Bore et al,9 where a silyl ether at C-23 was
converted with RuO4 into an acid and an aldehyde in 65% and 9% yield respectively.
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Scheme 2 a. Na2PdCl4, NaOAc, AcOH, rt, 88%. b. Ac2O, Et3N, DMAP, CH2Cl2, rt. c. pyridine, Pb(OAc)4, THF, AcOH then NaBH4, NaOH,
0 °C, 83% over two steps. d. Na2CO3, MeOH, rt, 95%. e. TiCl3, HCl, NH4OAc, H2O, THF, rt, 85%. f. SO3.py, Et3N, DMSO, rt, 52%.
As expected, the friedelin derived oxime 6 failed to undergo a successful cyclopalladation reaction, presumably
due to the unfavourable orientation of the single methyl group and/or the potential for -hydride elimination
from any resultant -organopalladium complex.
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Scheme 3 a. Na2PdCl4, NaOAc, AcOH, rt, 91%. b. Ac2O, Et3N, DMAP, CH2Cl2, rt. c. pyridine, Pb(OAc)4, THF, AcOH then NaBH4, NaOH,
0 °C, 81% over two steps.
The dimeric organopalladium complex 13 was obtained from the corresponding cholesterol derived oxime 5
using the same procedure described above. Surprisingly, oxidation of the corresponding acetate 14 with
Pb(OAc)4 in THF, followed by reductive workup with NaBH4 did not afford the expected diacetate 15. Instead,
the cyclopropane 16 was obtained in excellent yield, where stereoselective acetoxylation has occurred at C-6.
The introduction of an equatorial acetate unit at C-6 was evidenced by the appearance of a double doublet at 5.11
ppm with a large diaxial coupling in the 1H NMR, and the corresponding carbon atom at 70.2 ppm in the 13C
NMR. Similarly, the formation of the cyclopropane is consistent with the appearance of two signals at 0.81 ppm
and 1.30 ppm, correlating to the same carbon atom at 17.5 ppm, together with the low chemical shifts of the
resonances corresponding to C-4 and C-5.
Scheme 4 a. conc. H2SO4, reflux. b. KOtBu, MeI, tBuOH, reflux. c. NH2OH.HCl, NaHCO3, EtOH, reflux.
In order to further explore this unusual cyclopropane formation during the oxidation of the -organopalladium
intermediate, we prepared the simpler oximes 20 and 23 which also contain an alkene unit adjacent to the gem-
dimethyl unit (Scheme 4). The oxime 20 was obtained from known ketone 19, which was prepared via literature
methods.14-15 Oxime 23 was prepared by ZnCl2 mediated acylation of tetramethylethylene and subsequent
treatment of the ketone 2216 with hydroxylamine.
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Cyclopalladation of oxime 20 gave dimer 24, where the AB system corresponding to the CH2Pd unit can be
clearly observed at 2.50 ppm and 2.66 ppm with the corresponding carbon atom appearing in the HMQC
spectrum at 42.1 ppm. This confirms that cyclopropane formation does not take place during the
cyclopalladation reaction. Upon warming the NMR sample to 60 °C, the carbon resonances from both the oxime
carbon and the CH2PdCl carbon become considerably sharper, indicating that dynamic effects are responsible for
the very broad peak observed for the latter carbon atom at room temperature. Acylation of 24 and subsequent
oxidation of the acetate 25 gave the cyclopropane diacetate 26, in a similar manner to the cholesterol derivative
14 above, together with a small quantity of the chloroketone 27. The stereochemistry of the diacetate 26 is
consistent with the 1H coupling constants and was confirmed by nOe experiments in combination with 2D
correlation experiments.
Treatment of oxime 23 with Na2PdCl4 led to the formation of a yellow precipitate as for the other systems, but
without insertion into any of the methyl C-H bonds. The integrals in the 1H NMR spectrum indicated the
presence of four chemically inequivalent methyl groups, together with an alkene methylene unit. This suggests
that complexation of the palladium to the oxime has occurred as expected, but the expected C-H insertion
reaction has been prevented by complexation of the adjacent alkene unit to the palladium centre. This holds the
methyl groups away from the metal centre, thereby preventing reaction. Such complexation of the palladium by
the alkene unit is impossible in oximes 5 and 20 due to the rigid bicyclic ring system. The palladium complex 28
appeared to be exceptionally stable, and attempts to promote decomplexation of the alkene and subsequent C-H
insertion by heating the complex to reflux in methanol, ethanol or acetic acid, led only to slow degradation of the
complex. In contrast, a related palladium complex of an O-allyl oxime readily underwent alkoxypalladation in
alcoholic solvent.17
Scheme 5 a. Na2PdCl4, NaOAc, AcOH, rt, 85% (24), 52% (28). b. Ac2O, Et3N, DMAP, CH2Cl2, rt. c. pyridine, Pb(OAc)4, THF, AcOH then
NaBH4, NaOH, 0 °C, 64% (26), 23% (27) over two steps.
2.3. Mechanism of Cyclopropane formation
The cyclopropane formation must take place during the oxidation with lead tetraacetate as the cyclopropane is
clearly not present in the acetate 25, from examination of the crude 1H NMR. A plausible mechanism for the
cyclopropane formation is shown in Scheme 6. Transmetallation from palladium to lead gives the organolead
intermediate 29, which can rearrange via acetate transfer to form the cyclopropane 26. Coordination of the oxime
to the lead leads to a trigonal bipyrimidal geometry, which will favour the direct transfer of an apical acetate
ligand to the lower face of the alkene, leading to the observed stereochemistry in the product. Alternatively,
oxidation of the complex 25 to a Palladium (IV) intermediate 30 would promote a similar
rearrangement/reductive elimination of an acetate ligand to yield cyclopropane 26. Chloride 27 is formally
derived from palladium intermediate 25 by reductive elimination, perhaps via a lead-mediated radical
mechanism related to that of the Kochi modification of the Hunsdieker decarboxylation or via reductive
elimination of the palladium (IV) intermediate 30.18 Interestingly, Sutherland et al reported the formation of a
chloride by oxidation of the palladium complex derived from 2,2,6-trimethylcyclohexanone oxime with meta-
chlorobenzoic acid, perhaps providing evidence for the latter explanation.10a
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3. Conclusions
The selective functionalisation of the hindered C-4 equatorial methyl group in triterpenoids previously reported
for ursane, lupane and oleanane skeletons was successfully applied to the functionalisation of the lanostane
backbone. The palladium dimer was successfully elaborated to give 3-oxo-4-methyl-lanosta-8,24-diene-4-
carbaldehyde (12), a potential aglycon unit for the synthesis of novel adjuvant saponins.19 The presence of the C-
5 double bond in the cholestane skeleton interferes in the oxidation of the dimeric palladium complex, leading to
stereoselective cyclopropane formation and introduction of an equatorial acetate unit at C-6 (16). This unusual
transformation was also observed in a simpler decalin system (26), however the cyclopalladation of an open
chain unsaturated oxime was unsuccessful due to complexation of the alkene group to the palladium and the
formation of a novel highly stable palladium complex (28).
4. Experimental
4.1. General methods
Melting points were determined using a Reichert hot-stage apparatus and are uncorrected. Infrared (IR) spectra
were recorded on a Perkin-Elmer 1605 Fourier transform spectrometer, and were recorded as thin films (NaCl
plate). 1H NMR spectra were recorded at 300 MHz on a Bruker AMX300 spectrometer, at 400 MHz on a Bruker
AMX400 spectrometer or at 500 MHz on a Bruker Avance 500 spectrometer in the stated solvent using residual
protic solvent CHCl3 ( = 7.26 ppm, s). Chemical shifts are quoted in ppm using the following abbreviations: s,
singlet; d, doublet; t, triplet; q, quartet; qn, quintet; m, multiplet; br, broad or a combination of these. The
coupling constants (J) are measured in Hertz. 13C NMR spectra were recorded at 75 MHz on a Bruker AMX300
spectrometer, at 100 MHz on a Bruker AMX400 spectrometer or at 125 MHz on a Bruker Avance 500
spectrometer in the stated solvent using the central reference of CHCl3 ( = 77.0 ppm, t) as the internal standard.
All solvents were dried using standard procedures and freshly distilled before use. Lead tetraacetate was
recrystallized from acetic acid. Zinc chloride was dried by heating to > 300 °C to fuse the solid and was stored in
a glove box. Other reagents were commercially available and used directly without purification.
Chromatographic separations were performed with silica gel 60 (230-400 mesh) and thin-layer chromatography
and performed on polyester backed sheets coated with silica gel 60 F254, both supplied by Merck.
4.2. General procedure for the synthesis of oximes
A solution of the corresponding ketone (1.0 eq.), hydroxylamine hydrochloride (1.0 eq.), sodium hydrogen
carbonate (1.2 eq.) and ethanol (10 mL/mmol) was refluxed for 12-24 hours. After cooling to room temperature,
water was added (10 mL/mmol) and the mixture extracted with dichloromethane (3 × 15 mL/mmol). The
combined organic phases were dried over MgSO4, filtered and evaporated in vacuum. The resulting product was
purified by chromatography on a silica gel column, using petroleum ether/dichloromethane (7:3) as eluent.
4.2.1. Lanosta-8,24-dien-3-one oxime (4)
 = 82%; mp 169-172 ºC; IR (KBr) 3272, 2949, 2868, 1652, 1559, 1458, 1373, 949 cm-1; 1H NMR (500 MHz,
CDCl3):  0.70 (s, 3H, H-18), 0.80-0.95 (m, 2H, H-16), 0.86 (s, 3H, H-19), 0.91 (d, J = 6.0 Hz, 3H, H-21), 1.00-
1.50 (m, 9H, H-1, H-5, H-12, H-15, H-17, H-20, H-22), 1.09 (s, 3H, H-28), 1.10 (s, 3H, H-29), 1.16 (s, 3H, H-
30), 1.60 (s, 3H, H-27), 1.65-1.75 (m, 2H, H-6), 1.68 (s, 3H, H-26), 1.80-2.05 (m, 8H, H-1, H-7, H-11, H-12, H-
23), 2.10-2.30 (m, 1H, H-2), 3.125 (dt, J = 4,0 J = 15,3 Hz, 1H, H-2), 5.10 (t, J = 5,7 Hz, 1H, H-24); 13C NMR
(100 MHz, CDCl3):  15.78 (C-18), 17.62 (C-27), 17.62 (C-30), 18.61 (C-2), 18.73 (C-21), 18.73 (C-28), 18.92
(C-6), 21.06 (C-11), 23.01 (C-29), 24.09 (C-16), 24.23 (C-19), 24.90 (C-23), 25.71 (C-26), 26.35 (C-7), 28.15
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(C-12), 35.63 (C-22), 36.13 (C-10), 36.23 (C-20), 36.32 (C-15), 36.46 (C-1), 40.38 (C-4), 44.43 (C-13), 49.82
(C-14), 50.35 (C-5), 50.47 (C-17), 125.21 (C-24), 130.90 (C-25), 133.76 (C-8)a, 134.83 (C-9)a, 167.11 (C-3); m/z
(FAB+) 441 (M+H+, 89.4), 145 (12.9), 95 (32.4), 69 (100.0); Anal. Calcd for C30H49NO (439.72): C, 81.94; H,
11.23; N, 3.19. Found: C, 81.55; H, 11.17; N, 3.62.
4.2.2. 4,4-Dimethylcholest-5-en-3-one oxime (5).
 = 60%; mp 224-226 ºC; IR (KBr) 3315, 2948, 2869, 1652, 1543, 1459, 1380, 950 cm-1; 1H NMR (500 MHz,
CDCl3):  0.61 (s, 3H, H-18), 0.77 (s, 3H, H-19), 0.796 (d, J = 6.5 Hz, 3H, H-26)a, 0.799 (d, J = 6.5 Hz, 3H, H-
27)a, 0.80-2.20 (m, 20H, H-8, H-9, H-11, H-12, H-14, H-15, H-16, H-17, H-20, H-22, H-23, H-24, H-25), 0.85
(d, J = 6.5 Hz, 3H, H-21), 1.19 (s, 3H, H-28)b, 1.20-1.40 (m. 1H, H-1), 1.27 (s, 3H, H-29)b, 1.40-1.60 (m, 1H, H-
7), 1.70-1.90 (m, 1H, H-1), 1.90-2.10 (m, 1H, H-7), 2.31 (dd, J = 7.1, 19.0 Hz, 1H, H-2), 2.88 (ddd, J = 8.5,
12.0, 19.0 Hz, 1H, H-2), 5.50 (dd, J = 2.2, 5.0 Hz, 1H, H-6); 13C NMR (100 MHz, CDCl3):  12.3 (C-18), 19.1
(C-21), 19.3 (C-19), 19.7 (C-2), 21.8 (C-11), 22.9 (C-26)a, 23.2 (C-27)a, 24.3 (C-23), 24.6 (C-15), 28.4 (C-16),
28.6 (C-28), 28.7 (C-29), 30.9 (C-1), 31.2 (C-25), 32.2 (C-7), 33.9 (C-8), 36.2 (C-20), 36.6 (C-22), 37.6 (C-10),
39.9 (C-24), 40.3 (C-12), 41.6 (C-4), 42.8 (C-13), 49.5 (C-9), 56.6 (C-17), 57.4 (C-14), 119.3 (C-6), 150.3 (C-5),
166.5 (C-3); m/z (FAB+) 428 (M+H+, 65.2), 107 (90.1), 69 (100.0), 55 (68.1); Anal. Calcd for C29H49NO
(427.71): C, 81.44; H, 11.55; N, 3.27. Found: C, 81.66; H, 11.43; N, 3.16.
4.2.3. Friedelan-3-one oxime (6)
 = 68%; mp 290-294 ºC; 1H NMR (500 MHz, CDCl3):  0.74 (s, 3H, H-24), 0.84 (s, 3H, H-25), 0.85-0.90 (m,
1H, H-22), 0.94 (d, J = 6.6 Hz, 3H, H-23), 0.95 (s, 3H, H-29), 1.00 (s, 6H, H-26 and H-30), 1.03 (s, 3H, H-27),
1.17 (s, 3H, H-28), 1.15-1.65 (m, 24H, H-1, H-2, H-4, H-6, H-7, H-8, H-9, H-10, H-11, H-12, H-15, H-16, H-18,
H-19, H-21, H-22), 1.77 (d, J = 13.0 Hz, 1H, H-2), 2.02 (q, J = 6.6 Hz, 1H, H-4), 3.43 (ddd, J = 1.5, 4.2, 13.0
Hz, 1H, H-2); 13C NMR (100 MHz, CDCl3):  8.36 (C-23), 14.21 (C-24), 17.96 (C-25), 18.34 (C-7), 18.66 (C-
27), 20.24 (C-26), 20.53 (C-2), 24.42 (C-1), 28.17 (C-20), 30.01 (C-17), 30.54 (C-12), 31.78 (C-30), 32.09 (C-
28), 32.40 (C-15), 32.78 (C-21), 35.03 (C-29), 35.33 (C-19), 35.56 (C-11), 36.03 (C-16), 37.29 (C-9), 38.30 (C-
14), 39.26 (C-22), 39.66 (C-13), 40.29 (C-5), 41.15 (C-6), 42.78 (C-18), 50.96 (C-4), 53.09 (C-8), 59.99 (C-10),
162.36 (C-3).
4.2.4. (E)-1,1,4a-Trimethyl-3,4,4a,5,6,7-hexahydronaphthalen-2(1H)-one oxime (20)
 = 83%; mp 65-66 ºC; IR (film) 3281, 2972, 2930, 2866, 1456, 1435, 1383, 939 cm-1; 1H NMR (400 MHz,
CDCl3):  0.93 (s, 3H, Me), 1.26 (s, 3H, Me), 1.28-1.35 (m, 4H, Me and CHH), 1.47 (br dt, J = 12.7, 3.3 Hz, 1H,
CHH), 1.53-1.72 (m, 4H, 2 × CH2), 1.96-2.12 (m, 2H, CH2CH=C), 2.39 (ddd, J = 18.8, 6.2, 2.9 Hz, 1H,
CHHC=NOH), 3.01 (ddd, J = 18.8, 11.2, 9.0 Hz, 1H, CHHC=NOH), 5.57 (dd, J = 4.1, 3.2 Hz, 1H, CH=C), 9.75
(br s, 1H, OH); 13C NMR (100 MHz, CDCl3):  18.2 (CH2), 19.4 (CH2), 23.8 (Me), 25.6 (CH2), 28.0 (Me), 32.7
(Me), 34.07 (CH2CMe), 34.10 (CH2), 38.9 (CH2), 41.2 (CC=NOH), 119.5 (CH=C), 148.9 (CH=C), 165.8
(C=NOH); m/z (EI) 208 ([M+H]+, 100), 179 (26); HRMS: [M+H]+, found 208.17052, C13H21NO requires
208.17014; Anal. Calcd for C13H21NO: C, 75.32; H, 10.21; N, 6.76. Found: C, 75.36; H, 10.37; N, 6.84.
4.2.5. (E)-3,3,4-Trimethylpent-4-en-2-one oxime (23)
Anhydrous zinc chloride (4 g, 29.3 mmol) was added portionwise to a mixture of tetramethylethylene (7 mL,
58.9 mmol) and acetic anhydride (56 mL, 589 mmol) under nitrogen atmosphere at 0 °C. The reaction mixture
was allowed to warm to room temperature and stirred for 20 h. Saturated sodium carbonate (100 mL) was then
added slowly and the mixture stirred for 20 min then extracted with hexane (3 × 100 mL). The combined organic
layers were washed with brine (100 mL), dried (MgSO4) and concentrated to give 3,3,4-trimethylpent-4-en-2-
one as a brown liquid. Sodium bicarbonate (17.98 g, 214 mmol) and hydroxylamine hydrochloride (12.41 g,
176.7 mmol) were added to a solution of the crude ketone in ethanol (140 mL) which was heated to reflux for 20
h. After cooling, water (100 mL) was added and the mixture extracted with dichloromethane (3 × 100 mL) and
the combined organic layers washed with brine (100 mL), dried (MgSO4), and concentrated. The crude product
was purified by column chromatography (10:1 Petrol:Ether) to give the oxime as a low-melting point white solid
(3.83 g, 46% over two steps).
 = 46%; mp 27-28 ºC; IR (film) 3300, 2974, 1699, 1639, 1456, 1379, 1134, 1024, 999, 935 cm-1; 1H NMR (500
MHz, CDCl3)  1.25 (6H, s, 2 × Me), 1.64 (3H, s, Me), 1.76 (3H, s, Me), 4.88-4.89 (2H, m, CH2); 13C NMR
(125 MHz, CDCl3):  10.7, 19.7, 24.5, 46.3, 111.0, 149.4, 162.3; m/z (CI) 142 ([M+H]+, 80), 126 ([M-CH3]+,
100), 109 (40), 83 (62); HRMS: [M+H]+, found 142.12266, C8H15NO requires 142.12318.
4.3. General procedure for the synthesis of dimers
Sodium acetate (1.1 eq.) and Na2PdCl4 (1.12 eq.) were added to a solution of the oxime (1.0 eq.) in acetic acid
(40 mL/mmol). The solution was allowed to stir at room temperature under nitrogen atmosphere for 72 h. Ice
cold water (45 mL/mmol) was added to give a yellow precipitate which was filtered and dried in vacuum, at 60
ºC over P2O5, for 24 h. The corresponding dimer was obtained as an amorphous solid which was directly used in
the following step without any additional purification.
4.3.1. Chloro-bis(lanost-8,24-dien-3-one-C30,N) oxime dipalladium (II) complex (7)
 = 88%; mp  300 ºC; IR (KBr) 3375, 2951, 1652, 1559, 1458, 1373, 952 cm-1; 1H NMR (500 MHz, CDCl3): 
0.68 (s, 3H, H-18), 0.87 (s, 3H, H-19), 0.89 (br d, J = 7.5 Hz, 3H, H-21), 1.00-1.50 (m, 5H, H-1, H-15 and H-
20), 1.05 (br s, 3H, H-28), 1.25-1.50 (m, 5H, H-5, H-12, H-16 and H-17), 1.28 (br s, 3H, H-29), 1.50-1.75 (m,
3H, H-6 and H-23), 1.60 (s, 3H, H-27), 1.68 (br s, 3H, H-26), 1.75-2.20 (m, 9H, H-2, H-6, H-7, H-11, H-12 and
H-22), 2.25-2.75 (m, 2H, H-30), 2.90-3.10 (m, 1H, H-2), 5.09 (br s, 1H, H-24), 8.10 (br s, -OH); 13C NMR (100
MHz, CDCl3):  15.8 (C-18), 18.00 (C-6), 18.00 (C-27), 18.70 (C-21), 18.70 (C-28), 20.5 (C-2), 21.3 (C-11),
23.3 (C-29), 24.1 (C-16), 24.2 (C-19), 24.9 (C-23), 25.7 (C-26), 26.0 (C-7), 28.1 (C-12), 35.3 (C-22), 36.2 (C-
20), 36.40 (C-1), 36.40 (C-15), 37.4 (C-10), 44.4 (C-13), 49.9 (C-14), 50.3 (C-5), 50.4 (C-17), 51.8 (C-4), 125.2
(C-24), 130.9 (C-25), 132.8 (C-8)a, 135.5 (C-9)a, 177.7 (C-3); Anal. Calcd for C60H96N2O2Pd2Cl2 (1161.18): C,
61.26; H, 8.51; N, 2.46. Found: C, 61.10; H, 8.54; N, 2.20.
4.3.2. Chloro-bis(4,4-dimethylcolest-5-en-3-one-C29,N) oxime dipalladium (II) complex (13)
 = 91%; mp  300 ºC; IR (KBr) 3402, 2950, 1651, 1543, 1458, 1380, 954 cm-1; 1H NMR (500 MHz, CDCl3): 
0.89 (s, 3H, H-18), 1.00-2.00 (m, 22H, H-1, H-8, H-9, H-11, H-12, H-14, H-15, H-16, H-17, H-20, H-22, H-23,
H-24, H-25), 1.02 (s, 3H, H-19), 1.07 (d, J = 6.6 Hz, 6H, H-26 and H-27), 1.11 (d, J = 6.3 Hz, 3H, H-21), 1.72
(s, 3H, H-28), 2.00-3.00 (m, 6H, H-2, H-7, H-29), 5.64-5.66 (m, 1H, H-6), 8.36 (br s, -OH); 13C NMR (100
MHz, CDCl3):  12.4 (C-18), 19.10 (C-19), 19.10 (C-21), 21.5 (C-11), 22.1 (C-2), 22.9 (C-26)a, 23.2 (C-27)a,
24.2 (C-23), 25.5 (C-15), 28.4 (C-29), 28.6 (C-16), 29.9 (C-1), 31.7 (C-25), 31.9 (C-7), 34.3 (C-8), 36.2 (C-20),
36.6 (C-22), 38.4 (C-10), 39.9 (C-24), 40.2 (C-12), 42.7 (C-13), 48.5 (C-9), 52.9 (C-4), 56.6 (C-17), 57.2 (C-14),
120.4 (C-6), 149.2 (C-5), 177.1 (C-3); Anal. Calcd for C58H96N2O2Pd2Cl2 (1137.15): C, 61.26; H, 8.51; N, 2.46.
Found: C, 61.10; H, 8.54; N, 2.20.
4.3.3. Chloro-bis(1,1-dimethyl-3,4,4a,5,6,7-hexahydronaphthalen-2-one-C2,N) oxime dipalladium (II)
complex (24)
 = 85%; mp 115-117 ºC (dec); IR (film) 3373, 2959, 2928, 2866, 1558, 1423, 1400, 1379, 1364, 1288, 1097,
999 cm-1; 1H NMR (500 MHz, CDCl3):  0.90 (s, 3H, Me), 1.29 (td, J = 12.9, 4.3 Hz, 1H, CHHCMe), 1.46-1.55
(m, 6H, Me, CHHCMe and CH2CMe), 1.59-1.68 (m, 2H, CH2CH2CMe), 1.92-1.97 (m, 2H, CH2CH=C), 2.36
(ddd, J = 20.2, 6.1, 2.7 Hz, 1H, CHHC=NOH), 2.47-2.53 (br m, 1H, CHHPd), 2.66 (d, J = 8.0 Hz, 1H, CHHPd),
2.81 (ddd, J = 20.2, 11.4, 8.9 Hz, 1H, CHHC=NOH)), 5.45 (dd, J = 4.3, 3.1 Hz, 1H, CH=C), 8.17 (br s, 1H,
OH); 13C NMR (100 MHz, CDCl3):  18.1 (CH2CH2CMe), 21.2 (CH2C=NOH), 23.0 (CH2CMe), 25.4
(CH2CH=C), 32.8 (CH2CH2C=NOH), 33.6 (MeCCH2Pd), 34.8 (CH2CMe), 37.4 (CH2CMe), (42.1, CH2Pd), 52.5
(CCH2Pd), 120.6 (CH=C), 147.7 (CH=C), 176.7 (C=NOH); m/z (FAB) 660 (MH+-Cl).
4.3.4. (3,3,4-Trimethylpent-4-en-2-one oxime-C4,C5,N) palladium dichloride (28)
 = 52%; mp 122-127 ºC (dec.); IR (film) 3260, 1558, 1427, 1375, 1055, 993 cm-1; 1H NMR (500 MHz, CDCl3):
 1.46 (s, 3H, Me), 1.61 (s, 3H, Me), 2.05 (s, 3H, Me), 2.14 (s, 3H, Me), 4.90 (s, 1H, CHH), 5.43 (s, 1H, CHH),
9.88 (s, 1H, OH); 13C NMR (125 MHz, CDCl3):  13.9, 22.9, 25.1, 25.9, 52.3, 84.2, 138.3, 174.2. m/z (CI) 317
(10, M+), 142 (98, M+H- Cl2Pd), 126 (100, M-CH3Cl2Pd); HRMS: [M]+, found 316.95716, C8H15ClNOPd
requires 316.98655.
4.4. General procedures for the synthesis of O-acetate of oximes
Triethylamine (5.72 eq.), DMAP (0.12 eq.), and acetic anhydride (5.72 eq.) were added to a stirred solution of
the dimer (1.0 eq.) in dry dichloromethane (54 mL/mmol), under nitrogen atmosphere. The mixture was stirred
at room temperature for 45 min, then washed with water (2 × 50 mL), dried over magnesium sulfate, filtered and
evaporated in vacuum to afford the acetate as a colourless oil which was used immediately in the following step.
Pyridine (3.5 eq.) and dry THF (54 mL/mmol) were added to this oil and the solution was stirred at room
temperature under nitrogen atmosphere for 15 min. The solution was cooled to 0 °C and a solution of lead tetra-
acetate (4.0 eq.) in acetic acid (27 mL/mmol) was added dropwise. The reaction mixture was allowed to warm
slowly to room temperature, and stirred for 16 h. A solution of sodium borohydride (4.0 eq.), in 1 N aqueous
NaOH solution (50 mL) was added and the mixture stirred for 10-15 min to precipitate palladium salts.
After the mixture was filtered, the filtrate was diluted with dichloromethane (250 mL) and washed with saturated
aqueous sodium hydrogen carbonate solution until AcOH was completely removed, dried over magnesium
sulfate, filtered and evaporated in vacuum.
The solid residue was purified by flash column chromatography of silica gel using petroleum ether/ethyl acetate
(2:1) as eluent, to give O-acetate of the corresponding oxime.
4.4.1. 3-Acetoxy-imino-30-acetoxylanost-8,24-diene (9)
 = 83%; mp 119-122 ºC; IR (KBr) 2961, 1773, 1738, 1621, 1468, 1373, 1238, 1204, 935 cm-1; 1H NMR (500
MHz, CDCl3):  0.70 (s, 3H, H-18), 0.85-0.95 (m, 2H, H-16), 0.89 (s, 3H, H-19), 0.92 (d, J = 6.3 Hz, 3H, H-21),
1.00-1.25 (m, 2H, H-15), 1.06 (s, 3H, H-28), 1.20 (s, 3H, H-29), 1.25-1.50 (m, 3H, H-12, H-17 and H-20), 1.25-
1.65 (m, 5H, H-1, H-6 and H-22), 1.50-1.65 (m, 1H, H-5), 1.61 (s, 3H, H-27), 1.65-2.00 (m, 4H, H-1, H-11 and
H-12), 1.69 (s, 3H, H-26), 1.90-2.10 (m, 4H, H-7 and H-23), 2.05 (s, 3H, H-2’’), 2.18 (s, 3H, H-2’), 2.56 (ddd, J
= 7.2, 10.5, 16.6 Hz, 1H, H-2), 2.82 (ddd, J = 3.7, 7.2 and 16.6 Hz, 1H, H-2), 4.18 (AB system, J = 11.4 Hz, 2H,
H-30), 5.10 (t, J = 7.0 Hz, 1H, H-24); 13C NMR (100 MHz, CDCl3):  15.86 (C-18), 18.60 (C-21), 18.71 (C-28),
18.90 (C-29), 19.01 (C-27), 19.16 (C-6), 20.61 (C-2), 20.01 (C-2’), 20.93 (C-2’’), 21.03 (C-11), 24.07 (C-16),
24.23 (C-19), 24.88 (C-23), 25.69 (C-26), 26.08 (C-7), 28.10 (C-12), 34.10 (C-1), 34.10 (C-22), 36.20 (C-20),
36.29 (C-15), 36.72 (C-10), 44.04 (C-4), 44.40 (C-13), 44.67 (C-5), 49.90 (C-14), 50.34 (C-17), 67.89 (C-30),
124.15 (C-24), 130.92 (C-25), 132.81 (C-8), 135.45 (C-9), 169.75 (C-3), 170.64 (C-1’), 170.93 (C-1’’); m/z
(FAB+) 540 (M+H+, 6.2), 482 (32.1), 422 (30.9), 198 (14.5), 145 (25.2), 95 (67.1), 69 (100.0); Anal. Calcd for
C34H53NO4 (539.80): C, 75.65; H, 9.90; N, 2.59. Found: C, 74.93; H, 9.78; N, 2.62.
4.4.2. 3-Acetoxy-imino-6-acetoxy-4-methyl-5,29-cyclo-cholestane (16)
 = 81%; IR (KBr) 2972, 1777, 1739, 1628, 1472, 1381, 1239, 1208, 936 cm-1; 1H NMR (500 MHz, CDCl3): 
0.67 (s, 3H, H-18), 0.80-1.00 (m, 1H, H-9), 0.81 (d, J = 5.9 Hz, 1H, H-29), 0.85 (d, J = 5.0 Hz, 3H, H-26)a, 0.85
(d, J = 5.0 Hz, 3H, H-27)a, 0.87 (d, J = 5.0 Hz, 3H, H-21), 0.90-1.10 (m, 1H, H-20), 1.07 (s, 3H, H-19), 1.00-
1.20 (m, 4H, H-7, H-14, H-15 and H-17), 1.10-1.25 (m, 3H, H-12 and H-24), 1.20-1.30 (m, 1H, H-16), 1.20-1.40
(m, 8H, H-1, H-11, H-22, H-23 and H-29), 1.40-1.60 (m, 3H, H-1, H-15 and H-25), 1.60-1.80 (m, 1H, H-8), 1.61
(s, 3H, H-28), 1.70-2.00 (m, 1H, H-7), 1.75-1.90 (m 1H, H-16), 1.90-2.00 (m, 1H, H-12), 2.04 (s, 3H, H-2’’),
2.19 (s, 3H, H-2’), 2.25-2.35 (m, 1H, H-2), 2.40-2.50 (m, 1H, H-2), 5.51 (dd, J = 3.3 and 12.3 Hz, 1H, H-6); 13C
NMR (100 MHz, CDCl3):  11.98 (C-18), 16.27 (C-19), 17.48 (C-29), 18.61 (C-21), 19.91 (C-28), 20.13 (C-2),
21.50 (C-2’’), 22.05 (C-11), 22.53 (C-26), 22.53 (C-27), 22.78 (C-2’), 23.74 (C-23), 23.94 (C-15), 26.64 (C-4),
27.26 (C-1), 27.98 (C-25), 28.10 (C-16), 35.37 (C-8), 35.68 (C-20), 36.06 (C-22), 36.37 (C-7), 36.93 (C-10),
39.46 (C-24), 39.61 (C-12), 40.59 (C-5), 42.79 (C-13), 46.27 (C-9), 55.73 (C-14), 56.08 (C-17), 70.19 (C-6),
169.23 (C-3), 169.96 (C-1’’), 170.13 (C-1’); m/z (FAB+) 528 (M+H+, 87.7), 470 (25.7), 444 (10.6), 408 (30.1),
154 (100.0); Anal. Calcd for C33H53NO4 (527.79): C, 75.10; H, 10.12; N, 2.65. Found: C, 74.75; H, 10.08; N,
2.33.
4.4.3. (±)-(1aS,4aS,8S,8aR)-1a,4a-Dimethyl-2-(acetoxyimino)-decahydrocyclopropanaphthalen-8-yl acetate
(26)
 = 64%; mp 77 ºC; IR (film) 2937, 1771, 1738, 1456, 1367, 1238, 1033, 932 cm-1; 1H NMR (500 MHz,
CDCl3):  0.82 (d, J = 5.7 Hz, 1H, CHHCMeC=N), 1.13 (s, 3H, CH2CMeCH2), 1.17-1.22 (m, 1H,
CHHCMeCH2), 1.26 (ddd, J = 14.8, 8.2, 2.0 Hz, 1H, CHHCH2C=N), 1.28 (d, J = 5.7 Hz, 1H, CHHCMeC=N),
1.43 (ddd, J = 13.2, 12.9, 4.7 Hz, 1H, CHHCMeCH2), 1.45 (ddd, J = 14.8, 12.0, 7.6 Hz, 1H, CHHCH2C=N),
1.53 (dddd, J = 13.2, 12.6, 12.0, 6.9 Hz, 1H, CHHCHOAc), 1.62 (s, 3H, MeCC=NOAc), 1.75 (ddddd, J = 13.2,
7.3, 6.9, 4.7, 2.5 Hz, 1H, CHHCH2CHOAc), 1.84 ((qdd, J = 13.2, 4.7, 4.4 Hz, 1H, CHHCH2CHOAc), 1.91-1.96
(m, 1H, CHHCHOAc), 2.05 (s, 3H, Me), 2.18 (s, 3H, Me), 2.44 (ddd, J = 19.9, 7.6, 2.0 Hz, 1H, CHHC=N), 2.57
(ddd, J = 19.9, 12.0, 8.2 Hz, CHHC=N), 5.44 (dd, J = 12.0, 3.0 Hz, 1H, CH=C); 13C NMR (125 MHz, CDCl3): 
16.3 (CH2CMeCH2), 17.8 (CH2CC=N), 19.9 (MeCO), 20.2 (CH2C=N), 20.6 (CH2CH2CHOAc), 21.5 (MeCO),
24.4 (MeCC=N), 26.7 (CC=N), 30.9 (CH2CHOAc), 32.0 (CH2CH2C=N), 33.4 (CH2CMeCH2), 34.6
(CH2CMeCH2), 39.1 (CCHOAc), 70.9 (CHOAc), 169.2 (C=N), 170.0 (C=O), 170.3 (C=O); m/z (CI) 308
([M+H]+, 31), 248 (29), 206 (78), 188 (100), 172 (67), 162 (42), 147 (37), 134 (62), 121 (32), 107 (43), 95 (70),
81 (52); HRMS: [M+H]+, found 308.18656, C17H25NO4 requires 308.18617.
4.4.4. O-Acetyl-1-(chloromethyl)-1,4a-dimethyl-3,4,4a,5,6,7-hexahydronaphthalen-2(1H)-one oxime (27)
 = 23%; IR (film) 2928, 2868, 1771, 1454, 1429, 1366, 1211, 1003, 926 cm-1; 1H NMR (500 MHz, CDCl3): 
0.97 (s, 3H, Me), 1.21-1.35 (m, 3H, CH2 and CHH), 1.36 (s, 3H, Me), 1.51-1.59 (m, 1H, CHH), 1.61-1.68 (m,
1H, CHH), 1.73 (ddddd, J = 17.0, 11.0, 9.8, 6.6, 3.5 Hz, 1H, CHH), 2.06 (dddd, J = 18.2, 10.7, 6.9, 2.8 Hz, 1H,
CHHCH=C), 2.15-2.22 (m, 1H, CHHCH=C), 2.24 (s, 3H, MeCO), 2.54 (ddd, J = 19.4, 6.5, 2.5 Hz, 1H,
CHHC=N), 2.93 (ddd, J = 19.4, 11.7, 8.3 Hz, 1H, CHHC=N)), 3.61 (d, J = 10.9 Hz, 1H, CHHCl), 4.16 (d, J =
10.9 Hz, 1H, CHHCl), 5.62 (dd, J = 4.4, 3.2 Hz, 1H, CH=C); 13C NMR (125 MHz, CDCl3):  17.9 (CH2), 20.1
(Me), 21.2 (CH2), 23.4 (Me), 25.6 (CH2), 30.6 (Me), 33.4 (CH2CMe), 33.8 (CH2), 38.8 (CH2), 47.3 (MeCC=N),
49.7 (CH2Cl), 122.0 (CH=C), 143.2 (CH=C), 168.6 (C=O), 170.1 (C=N); m/z (ES) 286 (43, MH+), 284 (100
MH+), 248 (43, M-Cl); HRMS: [M+H]+, found 284.14272, C15H22ClNO2 requires 284.14173.
4.5. 3-Hydroxy-imino-30-hydroxylanost-8,24-diene (10)
A solution of 3-acetoxy-imino-19-acetoxy-8,24-lanostadiene (7) (0.29 g, 0.51 mmol, 1.0 eq.) and sodium
carbonate (0.24 g, 2.27 mmol, 4.5 eq.) in methanol (40 mL) was stirred under nitrogen atmosphere at room
temperature for 24 h. After removal of methanol in vacuum, the resultant solid was dissolved in ethyl ether (20
mL) and a 1 N aqueous HCl solution was added (20 mL). The organic layer was washed three times with
saturated aqueous sodium hydrogen carbonate, dried over magnesium sulfate, filtered, and evaporated in vacuum
to give a solid. The solid was purified by flash column chromatography [petroleum ether-ethyl acetate (2:1)] to
give 3-hydroxy-ymino-30-hydroxylanosta-8,24-dieno (10) (0.22 g, 95 %), as a white solid.
Mp 182-185 ºC; IR (KBr) 3410, 2948, 2874, 1639, 1464, 1371, 1041, 933 cm-1; 1H NMR (500 MHz, CDCl3): 
0.71 (s, 3H, H-18), 0.85-0.95 (m, 2H, H-16), 0.87 (s, 3H, H-19), 0.92 (d, J = 6.3 Hz, 3H, H-21), 1.00-1.20 (m,
1H, H-1), 1.00-1.50 (m, 6H, H-12, H-15, H-20 and H-22), 1.08 (s, 3H, H-28), 1.14 (s, 3H, H-29), 1.30-1.50 (m,
1H, H-17), 1.40-1.60 (m, 1H, H-5), 1.50-1.80 (m, 4H, H-6 and H-23), 1.61 (s, 3H, H-27), 1.69 (s, 3H, H-26),
1.80-1.95 (m, 3H, H-1 and H-11), 1.85-2.00 (m, 1H, H-12), 1.95-2.15 (m, 3H, H-2 and H-7), 3.20 (ddd, J = 2.7,
4.6 and 15.5 Hz, 1H, H-2), 3.59 (AB system, J = 11.2 Hz, 2 H, H-30), 5.10 (t, J = 6.9 Hz, 1H, H-24), 7.80 (br s, -
OH); 13C NMR (100 MHz, CDCl3):  15.8 (C-18), 17.6 (C-27), 17.9 (C-2), 18.3 (C-28), 18.6 (C-21), 19.1 (C-
29), 18.9 (C-6), 21.2 (C-11), 24.1 (C-16), 24.3 (C-19), 24.9 (C-23), 25.7 (C-26), 26.1 (C-7), 28.2 (C-12), 35.2
(C-22), 35.2 (C-1), 36.3 (C-20), 36.3 (C-15), 36.9 (C-10), 44.9 (C-4), 44.4 (C-13), 45.6 (C-5), 49.9 (C-14), 50.4
(C-17), 67.7 (C-30), 125.2 (C-24), 130.9 (C-25), 133.6 (C-8), 135.1 (C-9), 166.7 (C-3); m/z (FAB+) 456 (M+H+,
73.4), 154 (37.3), 95 (66.9), 69 (100.0); Anal. Calcd for C30H49NO2 (455.72): C, 79.07; H, 10.84; N, 3.07.
Found: C, 79.12; H, 10.40; N, 3.31.
4.6. 30-Hydroxylanost-8,24-dien-3-one (11)
A buffered solution of titanium chloride (III) [1.30 mL of 20% aqueous hydrochloric acid solution containing
19% of titanium chloride (III)), ammonium acetate (0.775 g; 10.05 mmol; 27 eq.) and water (28 mL)] was added
to a solution of 3-hydroxy-imino-30-hydroxylanost-8,24-diene (10) (0.17 g; 0.373 mmol; 1.0 eq.) in THF (27
mL). The mixture was stirred at room temperature for 6 h.
The resulting aqueous solution was extracted three times with ether. The combined organic phases were washed
three times with saturated aqueous solution of sodium hydrogen carbonate, dried over magnesium sulfate,
filtered and evaporated to give a solid that was purified by flash column chromatography on silica gel (petroleum
ether:ethyl acetate, 7:3) to give to 30-hydroxylanost-8,24-dien-3-one (11) (0.14 g, 85%) as a white solid.
Mp 146-149 ºC; IR (KBr) 3434, 2943, 1699, 1462, 1374, 1056 cm-1; 1H NMR (500 MHz, CDCl3):  0.72 (s, 3H,
H-18), 0.85-0.95 (m, 2H, H-16), 0.89 (s, 3H, H-19), 0.92 (d, J = 6.3 Hz, 3H, H-21), 1.05 (s, 3H, H-28), 1.10-1.30
(m, 1H, H-12), 1.20-1.30 (m, 3H, H-15 and H-20), 1.22 (s, 3H, H-29), 1.30-1.50 (m, 1H, H-17), 1.50-1.80 (m,
2H, H-6), 1.61 (s, 3H, H-27), 1.69 (s, 3H, H-26), 1.85-1.95 (m, 1H, H-12), 1.91 (dd, J = 2.7 and 12.0 Hz, 1H, H-
5), 2.00-2.20 (m, 10H, H-1, H-7, H-11, H-22 and H-23), 2.31 (ddd, J = 2.7, 5.1 and 15.9 Hz, 1H, H-2), 2.55 (br
s, -OH), 2.67 (ddd, J = 6.6, 13.5 and 15.9 Hz, 1H, H-2), 3.55 (AB system, J = 11.1 Hz, 2H, H-30), 5.10 (t, J =
6.9 Hz, 1H, H-24); 13C NMR (100 MHz, CDCl3):  15.8 (C-18), 16.7 (C-28), 17.6 (C-27), 18.6 (C-21), 19.0 (C-
6), 19.1 (C-29), 21.2 (C-11), 24.1 (C-16), 24.3 (C-19), 24.9 (C-23), 25.7 (C-26), 26.0 (C-7), 28.2 (C-12), 35.7
(C-1), 35.9 (C-2), 36.2 (C-20), 36.3 (C-15), 36.5 (C-22), 36.7 (C-10), 44.5 (C-13), 45.1 (C-5), 49.9 (C-14), 50.4
(C-17), 52.3 (C-4), 66.9 (C-30), 125.2 (C-24), 131.0 (C-25), 133.1 (C-8), 135.6 (C-9), 219.4 (C-3); m/z (FAB+)
441 (M+H+, 33.1), 154 (35.4), 95 (61.3), 69 (100.0); Anal. Calcd for C30H48O2 (440.71): C, 81.76; H, 10.98.
Found: C, 81.60; H, 11.35.
4.7. 3-Oxo-4-methyl-lanost-8,24-dien-4-carbaldehyde (12)
A solution of sulfur trioxide/pyridine complex (70 mg, 0.44 mmol, 6.5 eq.) in dry dimethylsulfoxide (0.6 mL)
was added dropwise to a stirred solution of 30-hydroxylanost-8,24-dien-3-one (11) (30.0 mg, 0.068 mmol, 1.0
eq.) and triethylamine (0.19 mL; 1.36 mmol; 20.0 eq.) in dry dimethylsulphoxide (1mL) under nitrogen. After
addition, the reaction mixture was stirred under nitrogen atmosphere and at room temperature for about 1.5 h,
until total consumption of the starting material was observed by TLC. Ether (5 mL) was added and the phases
were separated. The organic phase was washed with 10 % aqueous sodium chloride solution.
A cold 10% aqueous sodium chloride was carefully added to the dimethylsulphoxide phase and the resulting
mixture was extracted with ether. The combined aqueous phases were extracted with ether and the combined
organic phases were dried over magnesium sulfate, filtered and evaporated under reduced pressure. The residue
was distilled under reduced pressure to give 3-oxo-4-methyl-lanost-8,24-dien-4-carbaldehyde (12) (15.5 mg,
52.4%) as a yellow oil.
IR (KBr) 2956, 2874, 1737, 1701, 1464, 1374 cm-1; 1H NMR (500 MHz, CDCl3):  0.70 (s, 3H, H-18), 0.80-0.90
(m, 2H, H-16), 0.89 (s, 3H, H-19), 0.90 (d, J = 6.5 Hz, 3H, H-21), 1.18 (s, 3H, H-28), 1.20-1.40 (m, 1H, H-12),
1.29 (s, 3H, H-29), 1.30-1.40 (m, 3H, H-15 and H-20), 1.40-1.50 (m, 1H, H-17), 1.50-1.70 (m, 2H, H-6), 1.59 (s,
3H, H-27), 1.60-1.80 (m, 3H, H-1 and H-22), 1.67 (s, 3H, H-26), 1.80-2.00 (m, 1H, H-12), 2.00-2.10 (m, 7H, H-
1, H-7, H-11 and H-23), 2.30 (dd, J = 2.4 and 12.9 Hz, 1H, H-5), 2.36 (ddd, J = 3.2, 5.9 and 15.9 Hz, 1H, H-2),
2.57-2.65 (m, 1H, H-2), 5,08 (ddt, J = 1.4, 2.7 and 4.2 Hz, 1H, H-24), 9.37 (s, 1H, CHO); 13C NMR (100 MHz,
CDCl3):  14.0 (C-29), 15.8 (C-18), 17.6 (C-27), 18.6 (C-21), 19.0 (C-28), 19.8 (C-6), 21.2 (C-11), 24.1 (C-16),
24.3 (C-19), 24.9 (C-23), 25.6 (C-7), 25.7 (C-26), 28.1 (C-12), 35.4 (C-2), 35.8 (C-10), 35.8 (C-22), 36.0 (C-1),
36.2 (C-15), 36.4 (C-20), 44.0 (C-5), 44.4 (C-13), 49.8 (C-14), 50.3 (C-17), 63.6 (C-4), 125.1 (C-24), 131.0 (C-
25), 132.7 (C-8), 135.9 (C-9), 200.2 (C-30), 212.4 (C-3); m/z (FAB+) 439 (M+H+, 45.2), 154 (24.7), 95 (51.9),
69 (100.0); Anal. Calcd for C30H46O2 (440.71): C, 82.14; H, 10.57. Found: C, 81.97; H, 10.72.
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